Projecting the fiscal impact of South Africa's contraceptive needs: Scaling up family planning post 2020.

BACKGROUND: Evidence-informed priority setting is vital to improved investment in public health interventions. This is particularly important as South Africa (SA) makes the shift to universal health coverage and institution of National Health Insurance. OBJECTIVES: To measure the financial impact of increasing the demand for modern contraceptive methods in the SA public health sector. We estimated the total cost of providing contraceptives, and specifically the budgetary impact of premature removals of long-acting reversible contraceptives. METHODS: We created a deterministic model in Microsoft Excel to estimate the costs of contraception provision over a 5-year time horizon (2018 - 2023) from a healthcare provider perspective. Only direct costs of service provision were considered, including drugs, supplies and personnel time. Costs were not discounted owing to the short time horizon. Scenario analyses were conducted to test uncertainty. RESULTS: The base-case cost of current contraceptive use in 2018 was estimated to be ZAR1.64 billion (ZAR29 per capita). Injectable contraceptives accounted for ~47% of total costs. To meet the total demand for family planning, SA would have to spend ~30% more than the estimate for current contraceptive use. In the year 2023, the 'current use' of modern contraceptives would increase to ZAR2.2 billion, and fulfilling the total demand for family planning would require ZAR2.9 billion. The base-case cost of implantable contraceptives was estimated at ZAR54 million. Assuming a normal removal rate, the use of implants is projected to increase by 20% during the 5-year period between 2019 and 2023, with an estimated 46% increase in costs. The cost of early removal of Implanon NXT is estimated at ZAR75 million, with total contraception costs estimated at ZAR102 million in 2019, compared with ZAR56 million when a normal removal rate is applied. CONCLUSIONS: The costs of scaling up modern contraceptives in SA are substantial. Early and premature removals of implantable contraceptives are costly to the nation and must be minimised. The government should consider conducting appropriate health technology assessments to inform the introduction of new public health interventions as SA makes the shift to universal health coverage by means of National Health Insurance.

Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review.

BACKGROUND: Combined oral contraceptives (COCs) increase the risk of venous thromboembolism (VTE), particularly among women with inherited clotting disorders. The World Health Organization classifies combined hormonal contraception as an "unacceptable health risk" for women with thrombogenic mutations but advises against universal thrombophilia screening before prescribing COCs given the low prevalence of thrombophilia and high screening costs. OBJECTIVE: Through the lens of lifetime costs and benefits, this paper systematically and critically reviews all published economic evaluations of thrombophilia screening prior to prescribing COCs. METHODS: We searched relevant databases for economic evaluations of thrombophilia screening before prescribing COCs. After extracting the key study characteristics and economic variables, we evaluated each article using the Quality of Health Economic Studies (QHES) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. RESULTS: Seven economic evaluations of thrombophilia screening before prescribing COCs met our inclusion criteria. Only the two economic evaluations focusing exclusively on selective screening exceeded the 75-point threshold for high-quality economic studies based on the QHES instrument, whereas only one of these exceeded the 85% CHEERS threshold. Only three of the seven economic evaluations performed sensitivity analysis on key parameters. Most studies underestimated the benefits of thrombophilia screening by comparing one-time costs of genetic screening against benefits per person-year, thus implicitly assuming a 1-year duration of COC use, neglecting the long-term implications of VTE and/or neglecting the lifetime benefits of awareness of inherited thrombophilia. CONCLUSION: Our review highlights the lack of methodologically rigorous economic evaluations of universal thrombophilia screening before prescribing COCs.

Permanent Contraception for Women.

Permanent contraception is a highly desired and commonly used contraceptive option for women around the world who desire never to become pregnant. Current methods of female permanent contraception require surgery. Postpartum tubal ligation and interval surgical tubal ligation are safe and effective, do not interfere with menstrual cycles, and require no ongoing cost or medical checkups. Hysteroscopic tubal occlusion offers a less invasive surgical approach, but requires an imaging study for verification of correct placement. However, not all women have access to a surgeon trained to provide permanent contraception, or they may face other prohibitive logistic or financial burdens. The development of novel permanent contraception methods that are immediately effective and/or nonsurgical could help improve access to and acceptability of permanent contraception. The expansion of permanent contraception options could help women achieve their family planning goals and reduce unintended pregnancies.

[Cost of family planning care in 10-19 years old teenagers]. / Costo de atención por servicios de planificación familiar a adolescentes de 10-19 años.

Objetives: To identify the costs of family planning care in adolescents. Material and methods: Longitudinal study of the cost of care for family planning carried out in 2015 in a group of individuals with age limits of 10 and 19 years in a unit first level of health care in the state of Queretaro, Mexico. The profile of use of family planning (FP) was created for the teen was performed services through counseling, provision of contraception and review of intrauterine device (IUD) in a year; cost projections for the population of adolescents and different coverage scenarios between 5 and 100% were made. Results: The average annual cost was 228.84 Mexican pesos. Ideally the identified cost was 2,708.94 pesos. The projection with 20 % coverage was 207,251,330 pesos. The average annual family planning consultations was 0.9. The most commonly used method was with medroxyprogesterone-estradiol at doses of 25 and 5 mg. Conclusion: The cost of planning in adolescents is low, taking into account the costs that the care of high-risk pregnancies and associated comorbidities.

Perceptions of and preferences for federally-funded family planning clinics.

BACKGROUND: The Title X family planning program provides affordable access to a range of sexual and reproductive health services, with a priority for low-income people. The disproportionate burden of unintended pregnancy, breast and cervical cancer, and sexually transmitted diseases among minority groups, teens, and young adults in the US underscore the need for affordable access to such services. However, increased access to sexual and reproductive health services, resulting from the Affordable Care Act (ACA) create questions regarding the continued need for this program. METHODS: A study was conducted to assess clients' perceptions of Title X-funded family planning clinics and their preferences for these clinics for a range of sexual and reproductive health services. An anonymous, self-administered, paper-and-pencil survey was administered to 696 clients who received services from one of eight Title X-funded family planning clinics in Northeast Ohio. RESULTS: The majority of participants stated very positive perceptions of the Title X-funded clinics; that they "Always" go to the Title X-funded clinic for birth control, STD/HIV testing, and pregnancy testing; and that the Title X-funded clinic was their regular source of health care. Females were more likely than males to prefer the Title X clinic for birth control, physical exams, pregnancy testing, and health information and more teens under the age of 18 preferred to use the Title X clinic for STD/HIV testing, physical exams, pregnancy testing, and health information. CONCLUSIONS: Findings indicate that these Title X-funded family planning clinics successfully reached populations in need of sexual and reproductive health services and suggest that these facilities can help play an important role in reducing disparities even after full implementation of the Affordable Care Act. However, more research is needed to fully quantify the need and value of Title X-funded family planning clinics and its relation to the changing health care environment in the US.

Vasectomy as a reversible form of contraception for select patients.

INTRODUCTION: To provide an effective form of birth control, men may choose a reversible or permanent form of contraception. Vasectomy is presently offered as a permanent option for male contraception. We have had patients who were interested in vasectomy and reversal as a temporary birth control option. The purpose of this paper is to determine if vasectomy should be offered for selected couples as a temporary form of contraception and under which circumstances. MATERIALS AND METHODS: A literature review was conducted to determine the available reversible contraceptive options, risks, failure rates and contraindications to each, and the risks and success rates of vasectomy and vasectomy reversal. RESULTS: Reversible contraceptives include hormonally based methods for women, non-hormonal anatomic barrier devices and spermatocidal agents. Hormone based therapies may be contraindicated in women with cardiovascular disease, hypertension, and some cancers. Non-hormonal contraceptives are generally less effective and may be unacceptable for some couples due to higher failure rates, difficulty of use and lack of acceptance. Both vasectomy and vasectomy reversal are low risk procedures. Reversal may be performed with a high degree of success, particularly with a short obstructive interval (97% patency if performed < 3 years following vasectomy). CONCLUSION: While vasectomy should be considered a permanent form of sterilization for most couples, there are select couples, unable or unwilling to use other forms of birth control, who would benefit from an informed discussion about using a vasectomy as a reversible form of contraception.

Costs and net health effects of contraceptive methods.

BACKGROUND: Pregnancy and contraceptive methods both have important health effects that include risks and benefits. The net impact of contraception on women's health has not been reported previously. STUDY DESIGN: This is a cost-utility analysis using a Markov model evaluated by Monte Carlo simulation using the societal perspective for costs. The analysis compared 13 methods of contraception to nonuse of contraception with respect to healthcare costs and quality-adjusted life years (QALYs). Discounting was applied for future costs and health effects. The base-case analysis applies to women of average health and fertility, ranging from 15 to 50 years of age, who are sexually active in a mutually monogamous relationship; smoking rates observed in women of reproductive age were used. Sensitivity analysis extended the analysis to nonmonogamous status and smoking status. RESULTS: Compared with use of no contraception, contraceptive methods of all types result in substantial cost savings over 2 years, ranging from US$5907 per woman for tubal sterilization to US$9936 for vasectomy and health gains ranging from 0.088 QALYs for diaphragm to 0.147 QALYs for depot medroxyprogesterone acetate. Compared with nonuse, even with a time horizon as short as 1 year, use of any method other than sterilization results in financial savings and health gains. Most of the financial savings and health gains were due to contraceptive effects. In a population of patients, even modest increases in the use of the most effective methods result in financial savings and health gains. CONCLUSIONS: Every method of contraception dominates nonuse in most clinical settings. Increasing the use of more effective methods even modestly at the expense of less effective methods will improve health and reduce costs. Methods that require action by the user less frequently than daily are both less costly and more effective than methods requiring action on a daily basis.

Financiamento dos programas de planejamento familiar no Brasil: estratégias econômicas de sustentaçäo / Financing of the family planning programs in Brazil: economic strategies of support

Discorre sobre planejamento familiar no Brasil. Apresenta a evoluçäo recente da populaçäo e politicas demograficas desenvolvidas. Apresenta estimativas da oferta, demanda e custos dos serviços de planejamento familiar. Analisa a questäo do financiamento e gastos dos programas de planejamento familiar e os esforços para a diversificaçäo do custeio dos programas (NMPM)

The value and use of different contraceptive methods.

Reductions in the rates of maternal and child mortality as well as in demographic growth are directly linked to contraceptive usage. The development and availability of safer, improved contraceptives which are convenient to use could be expected to be used by a larger group of individuals and thus make an impact on reproductive health as well as on population growth rates. Such arguments have been used to support contraceptive research. This article deals with some of the developments that have occurred as a consequence of such efforts.

PIP: Considerable research and development have been done to find new contraceptive modalities. Due to limited reproductive physiological events, however, few points of intervention exist. We have several decades of experience with barrier methods, sterilization, and steroidal contraceptives which disrupt the hypothalamo-hypophysio-gonadal axis and the local endometrial level. These methods are rather reliable. The newer synthetic steroids and drug delivery systems are not associated with the adverse side effects of the older generation of hormonal contraceptives. Developments in the synthesis of newer steroids may further reduce the adverse effects linked to today's generation of compounds. Contraceptive vaccines appear to provide as effective protection against pregnancy and to be more convenient than hormonal contraceptives. They do not induce a uniform response, however. Polyvaccines may overcome this. The emphasis on effecting complete azoospermia hinders development of male contraceptives. Intranasal administration of norethisterone and the FSH vaccine impair sperm function, and thus might be acceptable male contraceptives. Developed nations have been able to voluntarily limit family size and, in some cases, even achieve a negative growth rate with existing contraceptives. Economic development, adult literacy, and child welfare programs have also contributed to the decline in the birth rate. Considerable time is needed in developing countries to achieve the same state of economic development and optimal growth rates as those in developed countries. If population growth rates are not restrained in developing countries, abject poverty will be further entrenched. We really need to find newer, more safe and convenient contraception with fewer side effects. Thus, contraception research and development must continue with increased vitality. Such research often finds important medical uses for experimental contraceptives (e.g., contraceptive vaccines treat some types of cancer).

RU-486=Preguntas y respuestas / RU-486 Question and answer

Los fármacos con antiprogestina constituyen un nuevo método prometedor para el control de la natalidad. El RU-486, también conocido con el nombre de mifepristone, es el primer fármaco con antiprogestina disponible en el mercado. Hasta ahora se ha aprobado en Francia y China como alternativa no quirúrgica para terminar los embarazos en su etapa inicial. Siguen investigándose las distintas aplicaciones anticonceptivas del RU-486, que también parece tener varios otros usos terapéuticos. El RU-486 y otros fármacos parecidos pueden contribuir a eliminar las complicaciones relacionadas con las actuales técnicas quirúrgicas del aborto. Estos fármacos son potencialmente menos costosos y más aceptables para muchas mujeres que el aborto quirúrgico. Hoy en día, los expertos en medicina recomiendan usar el RU-486 dentro de un período de tres semanas después de producido el atraso menstrual y administrarlo junto con otro fármaco, la prostaglandina, la cual aumenta mucho su efectividad. En vista de que a veces se presentan problemas de hemorragias y abortos incompletos, el RU-486 debe tomarse bajo supervisión médica. El RU-486 podría reducir enormemente las defunciones por abortos practicados en condiciones deficientes en los países en desarrollo. Pero como este fármaco se ha convertido en objeto de considerables controversias, es probable que en muchos países su disponibilidad dependa de factores políticos

Whatever happened to the contraceptive revolution?

PIP: This article reviews the fates of various contraceptive methods since the modern era of contraception began in the 1950s. The recent experience with IUDs shows how easy it is to lose an existing method. Spermicides may be next. The pill, used by some 9-10 million American couples, looks firmly entrenched. Yet pill scares seem as enduring as the method: 2 of the most recent link oral contraceptives with increased vulnerability to AIDS and with breast cancer in women who took the pill prior to a 1st birth. Such scares could always endanger the availability of this product. The widespread concern about the AIDS epidemic represents both an opportunity for and a challenge to contraceptive development. Priorities in contraceptive research need to be reexamined to include methods that can deal simultaneously with unintended pregnancy and AIDS, as well as with less lethal sexually transmitted diseases. None of the new methods high in the research and development pipeline meet these criteria. The bright side of the picture is the number of promising leads for birth control methods that could be developed if there were adequate funding and if some of the other barriers to development were removed. Finally, the general public, health professionals, legislators and consumer and women's groups need a great deal of education on these issues.^ieng

Contracepção: percepção e prática / Contraception: perception and practice

A necessidade da elaboração do presente trabalho surge da problemática vivenciada na atuação junto a clientela feminina, em uma unidade básica do serviço público de saúde. Emerge principalmente da exigência de um posicionamento frente a demanda feminina por anticoncepção. Num momento em que estava ainda presente a polêmica acerca do controle da natalidade. Termo já de tal maneira pejorativo que as ações buscando uma mudnça coletiva no comportamento no sentido de controlar a prole eram denominadas de forma mais agráveis, por exemplo, como atividades no sentido de prover a "Paternidade Responsável"...

Elective hysterectomy. Benefits, risks, and costs.

This study evaluated the effect of hysterectomy or hysterectomy and bilateral salpingo-oophorectomy (hysterectomy and oophorectomy) versus alternative medical management on life expectancy, quality of life, and direct medical costs. Using techniques of decision analysis and available data on sequelae, it was found that gains in life expectancy and quality of life can be expected when women ages 30-60 undergo hysterectomy for benign neoplasm, disorders of menstruation, acquired abnormal anatomy, cervical disease, or endometriosis, owing primarily to prevention of reproductive tract cancers, which outweighs the impact of operative mortality. However, women who have relatively high operative risk or low expected cancer risks, beyond thresholds estimated in sensitivity analyses, suffer losses in life expectancy. Women younger than 35 not treated with replacement estrogens following hysterectomy and oophorectomy can expect net losses in life expectancy with surgical intervention due to increased risks of heart disease and osteoporosis. For women in the reproductive years who wish to preserve their potential to bear children, sterilization may be an unacceptable consequence of elective hysterectomy in the quality of life.